

# Cancer immunotherapies

Citation for published version (APA):

Ehlers, F. A. I. (2023). *Cancer immunotherapies: challenges and opportunities for NK cells in the tumor microenvironment*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20230216fe>

## Document status and date:

Published: 01/01/2023

## DOI:

[10.26481/dis.20230216fe](https://doi.org/10.26481/dis.20230216fe)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

## Propositions

belonging to the thesis “Cancer immunotherapies: challenges and opportunities for NK cells in the tumor microenvironment”

1. The level of HLA-E expression on tumor cells should be assessed for NK cell immunotherapy as high HLA-E levels inhibit NK cells but low HLA-E levels enhance NK cell responses *in vitro* (this thesis).
2. ADCC-triggering antibodies combined with KIR-HLA mismatched donor NK cells have the potential to improve NK cell-based immunotherapy considering the results in our *in vitro* models of both multiple myeloma and breast cancer (this thesis).
3. NK cell-based immunotherapy approaches using expanded NK cells are promising to target tumors that reside in a low glucose environment (this thesis).
4. NK cells degranulate and secrete IFN- $\gamma$  in response to *in vitro*-generated tumor-associated macrophages, suggesting that NK cell therapy can also be utilized to target and repolarize the immune-suppressive tumor microenvironment (this thesis).
5. Selection of the optimal therapeutic strategy for each individual patient will be a next step on the road to success of immunotherapies.
6. To achieve sustained anti-tumor effects, cell therapies of expanded and/or genetically engineered immune cells combined with antibodies or other drugs are required for the majority of cancers.
7. Remaining challenges of immunotherapies include tumor resistance mechanisms and the complexity and costs of manufacturing the immune cells for adoptive cell therapy.
8. Donor-derived expanded NK cells are an ideal source for adoptive cell therapy due to their enhanced anti-tumor activity and favorable cost effectiveness compared to autologous NK- or T cell approaches (Impact paragraph).
9. There is no real ending, it's just the place where you stop the story.  
Frank Herbert

Femke Ehlers  
16<sup>th</sup> of February 2023